Shingo Nasu1, Hidekazu Suzuki2, Takayuki Shiroyama2, Ayako Tanaka2, Kaori Iwata3, Noriko Ryota3, Yuki Ueda4, S O Takata2, Kentaro Masuhiro2, Satomu Morita2, Naoko Morishita2, Norio Okamoto2, Tomonori Hirashima2. 1. Department of Thoracic Oncology, Osaka Prefectural Hospital Organization Osaka Habikino Medical Center, Osaka, Japan hugurahoma@yahoo.co.jp. 2. Department of Thoracic Oncology, Osaka Prefectural Hospital Organization Osaka Habikino Medical Center, Osaka, Japan. 3. Department of Nursing, Osaka Prefectural Hospital Organization Osaka Habikino Medical Center, Osaka, Japan. 4. Department of Pharmacy, Osaka Prefectural Hospital Organization Osaka Habikino Medical Center, Osaka, Japan.
Abstract
BACKGROUND/AIM: Although afatinib has a strong efficacy, it can be toxic; hence, we aimed to determine markers of response to afatinib in order to assess prognosis. PATIENTS AND METHODS: Information on clinical background, therapeutic effects, and adverse events was collected retrospectively at one Institution from patients treated with afatinib as initial epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI). We examined the relationship between different adverse events and their effects on prognosis. RESULTS: Afatinib was used in 32 patients as the initial EGFR-TKI. Adverse events of grade 3 or higher including diarrhoea (12.5%), paronychia (6.3%), and stomatitis (3.1%) were experienced by patients. The median progression-free survival (PFS) was 15.4 months. A relationship between skin rash severity and PFS was observed. CONCLUSION: Grade 2 or higher skin rash might be a marker for long-term efficacy of afatinib when administered as a first-line treatment. Copyright
BACKGROUND/AIM: Although afatinib has a strong efficacy, it can be toxic; hence, we aimed to determine markers of response to afatinib in order to assess prognosis. PATIENTS AND METHODS: Information on clinical background, therapeutic effects, and adverse events was collected retrospectively at one Institution from patients treated with afatinib as initial epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI). We examined the relationship between different adverse events and their effects on prognosis. RESULTS:Afatinib was used in 32 patients as the initial EGFR-TKI. Adverse events of grade 3 or higher including diarrhoea (12.5%), paronychia (6.3%), and stomatitis (3.1%) were experienced by patients. The median progression-free survival (PFS) was 15.4 months. A relationship between skin rash severity and PFS was observed. CONCLUSION: Grade 2 or higher skin rash might be a marker for long-term efficacy of afatinib when administered as a first-line treatment. Copyright
Authors: Aminah Jatoi; Fang-Shu Ou; Daniel H Ahn; Tyler J Zemla; Jennifer G Le-Rademacher; Patrick Boland; Kristen K Ciombor; Nisha L Jacobs; Boris Pasche; James M Cleary; Jeannine S McCune; Katrina S Pedersen; Afsaneh Barzi; E Gabriela Chiorean; Erica N Heying; Heinz-Josef Lenz; Jeff A Sloan; Axel Grothey; Mario E Lacouture; Tanios Bekaii-Saab Journal: Oncologist Date: 2021-03-06